

NHS PRESCRIPTION AND REMUNERATION STATISTICS FOR ENGLAND AND WALES

	<u>2002/2003</u>		<u>2003/2004</u>		<u>2003/2004</u>	
	<u>August</u>	<u>April - August</u>	<u>August</u>	<u>April - August</u>	<u>August</u>	<u>April - August</u>
	<u>per Rx</u>	<u>per Rx</u>	<u>per Rx</u>	<u>per Rx</u>	<u>%</u>	<u>%</u>
Ingredient Cost	1087.43	1068.74	1130.45	1117.12	+4.0	+4.5
Less: Discount	-113.92	-111.82	-118.41	-117.51	+3.9	+5.1
Sub-total	973.51	956.92	1012.04	999.61	+4.0	+4.5
Container	<u>3.24</u>	<u>3.24</u>	<u>3.24</u>	<u>3.24</u>	<u>0.0</u>	<u>0.0</u>
Cost of Sales	<u>976.75</u>	<u>960.16</u>	<u>1015.28</u>	<u>1002.85</u>	<u>+3.9</u>	<u>+4.4</u>
Fees	100.11	100.11	97.78	97.73	-2.3	-2.4
Expensive Rx Allowance	2.37	2.30	2.56	2.50	+8.0	+8.7
Professional Allowance	<u>28.11</u>	<u>27.87</u>	<u>28.05</u>	<u>26.91</u>	<u>-0.2</u>	<u>-3.4</u>
Gross Profit	<u>130.59</u>	<u>130.28</u>	<u>128.39</u>	<u>127.14</u>	<u>-1.7</u>	<u>-2.4</u>
Total Payment/Rx	<u>1107.34</u>	<u>1090.44</u>	<u>1143.67</u>	<u>1129.99</u>	<u>+3.3</u>	<u>+3.6</u>
Gross Profit %	11.8	11.9	11.2	11.3	-0.6	-0.6
Rx Volume	51.523	260.470	51.771	270.838	+0.5	+4.0
	<u>£m</u>	<u>£m</u>	<u>£m</u>	<u>£m</u>	<u>%</u>	<u>£m</u>
Total NIC	560.277	2783.741	585.241	3025.598	+4.5	+8.7
Total Fees	51.580	260.745	50.621	264.680	-1.9	+1.5
Total Professional Allowance	14.485	72.593	14.522	72.890	+0.3	+0.4
Total Expensive Rx Allowance	<u>1.219</u>	<u>5.985</u>	<u>1.323</u>	<u>6.770</u>	<u>+8.5</u>	<u>+13.1</u>
Total Gross Profit	<u>67.284</u>	<u>339.323</u>	<u>66.466</u>	<u>344.340</u>	<u>-1.2</u>	<u>+1.5</u>

BALANCE SHEET

	<u>First Forecast 2003/04</u>	<u>Latest Forecast</u>	<u>% Change on 2002/03</u>	<u>Final 2002/03</u>
Rx Volume	658.2		+5.0	626.9
Total NIC	<u>7574.4</u>		+11.8	<u>6774.9</u>
Total Fees				624.0
Total Professional Allowance				174.2
Total Expensive Rx Allowance				<u>14.9</u>
Total Gross Profit				<u>813.1</u>

	<u>2002/3</u>	<u>2003/4</u>	<u>% change</u>
Rx Volume including LPS contractors			
August 2003	51.523	51.869	+0.7%
April to August 2003	260.470	271.395	+4.2%